Concerning CDK4/6 inhibitors, Gao et al. reported in their pooled analyses that CDK4/6 inhibitors were as effective for patients with ILC as for patients with IBC-NST in the metastatic setting39,40. Here, CDK4 is linked to inflammatory breast carcinoma.